| Literature DB >> 31287988 |
Irene Catalano1, Livio Trusolino2.
Abstract
In this issue of Cancer Cell, Woolston et al. show that colorectal cancers that become refractory to initially effective anti-EGFR therapy contain an abundance of stromal and immune cells, irrespective of the contextual presence of resistance-conferring mutations. This reconfiguration puts forward therapeutic opportunities for patients who relapse on EGFR-targeting treatment.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31287988 DOI： 10.1016/j.ccell.2019.06.001
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743